Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2021-05-24 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by RedHill Biopharma Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It includes a press release about analyses presented at a conference (DDW 2021). The document is short (2171 characters) and primarily serves as an announcement of the press release rather than containing detailed financial data or comprehensive report content. Form 6-K filings are typically regulatory filings used to disclose material information between annual reports for foreign issuers. Therefore, this document fits best under Regulatory Filings (RNS) as it does not contain a full report, financial statements, or detailed management discussion but is a regulatory disclosure of a press release.
2021-05-24 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a clinical severity classification tool and its use in efficacy analysis presented at a conference (DDW 2021). The document is short (2219 characters) and primarily serves as a regulatory filing to report this press release. It does not contain financial statements, detailed financial data, or management discussion. It also does not announce voting results, changes in management, or other specific report types. Given the nature of Form 6-K filings, which are used for current reports by foreign private issuers, and the content being a press release, this fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full report or presentation.
2021-05-21 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about hosting a webcast for first quarter 2021 financial results and operational highlights. The document is short (2192 characters) and primarily serves as an announcement of an event (webcast) rather than containing actual financial data or detailed financial results. It does not contain comprehensive financial statements or substantive financial analysis. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Interim Report. The document also does not meet the criteria for a Report Publication Announcement since it does not mention a report being attached or published, but rather announces a webcast event.
2021-05-20 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is a registration statement under the Securities Act of 1933 for securities to be issued under an employee benefit plan (Amended and Restated Award Plan). It includes detailed information about the securities to be registered, indemnification of directors and officers, and references to other filings such as the Annual Report on Form 20-F. This type of filing is a registration statement for employee stock plans and is not an annual report, earnings release, or other financial report. It is a regulatory filing related to securities registration and employee benefit plans, which does not fit into other specific categories like capital updates or management changes. Therefore, it is best classified as a Regulatory Filing (RNS).
2021-05-03 English
SC TO-I Filing
Regulatory Filings
2021-04-26 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a clinical study update, specifically a Phase 2/3 COVID-19 study passing a DSMB review. The document length is 2236 characters, which is relatively short and primarily serves as an announcement of a press release rather than containing detailed financial data or comprehensive report content. Form 6-K filings are typically used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. This document does not contain financial statements or detailed management discussion but is an announcement of a material event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-04-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.